Mehmet Hilmi Doğu

The outcome of COVID‐19 in patients with hematological malignancy

Tuğçe Nur Yiğenoğlu, Naim Ata, Fevzi Altuntaş et al. · Journal of Medical Virology · 2020 · 129 citations · Full text

Hematological Malignancy, Lymphoid Neoplasia, Intensive Care Unit +15

Nivolumab for relapsed or refractory Hodgkin lymphoma: real-life experience

Hüseyin Saffet Beköz, Nuri Karadurmuş, S. Paydaş et al. · Annals of Oncology · 2017 · 68 citations · Full text

Convalescent plasma therapy in patients with COVID-19

Fevzi Altuntaş, Naim Ata, Tuğçe Nur Yiğenoğlu et al. · Transfusion and Apheresis Science · 2020 · 65 citations · Full text

Covid-19 Pandemic, Convalescent Plasma Therapy, Covid-19 Epidemiology +3

Therapeutic plasma exchange in patients with neurological diseases: Multicenter retrospective analysis

Muzaffer Keklık, Mehmet Şencan, Alî Keskin et al. · Transfusion and Apheresis Science · 2013 · 51 citations

Neurodegenerative Diseases, Neurological Disorder, Plasma Donation +9

Outcome of COVID-19 in patients with chronic myeloid leukemia receiving tyrosine kinase inhibitors

Semih Başçı, Naim Ata, Fevzi Altuntaş et al. · Journal of Oncology Pharmacy Practice · 2020 · 40 citations · Full text